Literature DB >> 21789758

Pattern and predictors of false positive lymph node involvement on positron emission tomography in patients with non-small cell lung cancer.

Masaya Tamura1, Makoto Oda, Isao Matsumoto, Ryuichi Waseda, Go Watanabe.   

Abstract

Objectives The aim of this study was to elucidate the optimal parameters for diagnosing false positive (FP) lymph nodes (LNs) in patients with non-small cell lung cancer.Methods We reviewed 292 patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose positron emission tomography (FDG-PET) imaging was performed at 1 hour (early) post-FDG injection and repeated 2 hours (delayed) after injection. We analyzed the relationship between the pathology of LNs and the results of PET, and the percent change in the standardized uptake value (%ΔSUV) between the two time-points.Results Eighteen of 46 cases (39.1%) in the FP group showed higher SUVs for their LNs compared with those for primary tumor, whereas 13.2% in the true positive group (p = 0.032) had higher SUVs for their LNs. Thirty-four of 36 cases in the true positive group had %ΔSUV ranging from 0% to 61.5% compared with only 13 of 33 in the FP group. Twenty out of 22 cases (90.9%) where %ΔSUV was over 61.5% or under 0% were considered as FP.Conclusions Patients with higher SUVs for LNs than for primary tumors and patients with extremely high or low %ΔSUVs tended to have FP LNs. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21789758     DOI: 10.1055/s-0031-1280068

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  3 in total

1.  Clinical significance of post-treatment 18F-fluorodeoxyglucose uptake in cervical lymph nodes in patients with diffuse large B-cell lymphoma.

Authors:  Young-Sil An; Joon-Kee Yoon; Su Jin Lee; Seong Hyun Jeong; Hyun Woo Lee
Journal:  Eur Radiol       Date:  2016-05-18       Impact factor: 5.315

2.  Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.

Authors:  Michihiro Nakayama; Atsutaka Okizaki; Shunta Ishitoya; Miki Sakaguchi; Junichi Sato; Tamio Aburano
Journal:  Ann Nucl Med       Date:  2012-11-28       Impact factor: 2.668

3.  Non-small-cell lung cancer resectability: diagnostic value of PET/MR.

Authors:  Francesco Fraioli; Nicholas J Screaton; Samuel M Janes; Thida Win; Leon Menezes; Irfan Kayani; Rizwan Syed; Fulvio Zaccagna; Celia O'Meara; Anna Barnes; Jamshed B Bomanji; Shonit Punwani; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-15       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.